BioInvent and Genentech Initiate Phase I Clinical Trial for BI-204

BioInvent International AB has announced that they have received approval from the Danish Medicines Agency to initiate a Phase I clinical trial of BI- 204, a potential treatment for cardiovascular conditions brought on by atherosclerosis. The trial will be managed by BioInvent and carried out in Denmark, with the first subject expected to be recruited in the study imminently. BioInvent and Genentech, Inc. co-develop BI-204 under an agreement signed in January 2007. BI-204 is an antibody that targets oxidized forms of the harmful LDL cholesterol a key component thought to drive the inflammatory processes associated with atherosclerotic plaques. It is being developed as a drug for the secondary prevention of cardiac events, such as heart attack or stroke, in high-risk patients.

The Phase I study is a double-blind, within-group randomised dose-escalation trial testing both single and multiple doses of BI-204 administered either intravenously or subcutaneously. In total, 80 healthy male or female subjects with elevated levels of LDL cholesterol are planned to be included in the trial. In addition to monitoring the tolerability and safety of BI-204, the study will evaluate pharmacokinetic and pharmacodynamic parameters in order to help set the dosage of BI-204 administered to patients in future Phase II trials.

For further information please contact:

Svein Mathisen

President & CEO

Tel: +46 46-286 85 67

E-mail: svein.mathisen@bioinvent.com

Or visit: www.bioinvent.com